Genetika+ – A Pioneer in Personalized Medicine for Psychiatry – Raises $10 Million in an Oversubscribed Series A
Summary
The company is accelerating growth through increased hiring for multiple positions over the next 12 months in Boston and Israel to support research and business development activities across the U.S. market. “Millions of patients around the world face an arduous journey to find the most effective medication to treat their depression,” said Talia Cohen Solal, Ph.D., co-founder and CEO of Genetika+. We’re excited to secure this funding, which will enable the first biologically relevant measures to inform potentially life-changing medication selection decisions.” Depression affects daily functioning and quality of life for more than 300 million people worldwide, making it a leading cause of disability globally. Genetika+ is well positioned to solve this challenging problem and improve the lives of millions of patients worldwide.” About Genetika+ Genetika+, founded in 2018 by Talia Cohen-Solal, Ph.D., and Daphna Laifenfeld, Ph.D., is developing personalized medicine solutions to optimize treatment for psychiatric and neurological diseases. In its first indication, depression, Genetika+ uses patented technology to rapidly test more than 70 approved antidepressants and drug combinations against an individual patient’s unique neurological biomarkers.